JNJ - Johnson & Johnson
Johnson & Johnson posted strong Q2 earnings. Sales of its NMDA receptor antagonist, called Spravato, for the treatment of depression, rose 41.1% year-on-year to $584 million in Q2. Also, J&J raised its 2026 adjusted diluted EPS guidance from $11.45-$11.65 to $11.6-$11.75.
Few things ruin a Saturday morning faster than the words "your timing chain is going." Car repair bills arrive unannounced, cost more than expected, and have a way of landing the same week as property taxes or insurance renewals. The fix is a small, dedicated slice of capital whose only job is to absorb those... The Portfolio That Pays All Your Car Repairs For Life
Johnson & Johnson (NYSE:JNJ) shares rose in early trading on Thursday, after the company reported upbeat second-quarter results.
Johnson & Johnson raises its 2026 outlook after Q2 earnings and revenues beat estimates, driven by Innovative Medicine strength and pipeline momentum.
One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change to advance better care for all. Nominations for the inaugural TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson.
RAYNHAM, Mass.--(BUSINESS WIRE)--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes' Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment. Expanding Innovations (EI) is a commercial-stage medical technology company focused on developing and commercializing.
Twenty thousand dollars a month in dividends means $240,000 a year that has to arrive whether the market cooperates or not. Reaching it is a math problem before it is a stock-picking problem, and the math gets uncomfortable fast when you compare that target with current yields. The core equation is unforgiving: annual income divided... The Portfolio Blueprint for Building $20,000 a Month in Dividend Income
Ora Banda Mining Ltd (ASX:OBM, OTC:ESGFF) has closed FY2026 with record quarterly gold production, strong cash flow and a larger resource base. The company...
Many traded out of the pharmaceutical sector mainstay to leave it with a nearly 3% loss. While the company posted growth where it counts, the market seems to be expecting notable outperformance from large players in the industry these days.
Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression treatment, with Jefferies writing that the drug's commercial performance supports the long-term market opportunity for the sector. Johnson & Johnson (NYSE:JNJ) reported worldwide second-quarter Spravato (esketamine nasal spray) sales of $584 million, up 25% from the first quarter, including US sales of $514 million.
Johnson & Johnson NYSE: JNJ is an elite income investment because of its Dividend King status, healthy balance sheet, and incredibly strong, defensive business model. Critical details include its product portfolio and pipeline, which are producing numerous catalysts simultaneously in 2026.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is up 24.03% year to date and 65.92% over the past year, riding oncology strength and a raised full-year outlook.
Tech analyst Dan Ives announced that he has teamed up with Yorkville Securities to form a new kind of merchant bank. Johnson & Johnson (JNJ) beat Q2 estimates and raised guidance, but EPS decline weighed on sentiment despite innovative medicine strength.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike.
4:15pm: Apple surges, inflation cools Stocks finished higher on Wednesday as another softer-than-expected inflation report reinforced expectations that the...
The launch of artificial intelligence-powered imaging and mapping capabilities for electrophysiology, early momentum for a drug releasing system for bladder cancer treatment, and progress toward a table-integrated robotic surgical system are among the latest innovations from pharmaceuticals and MedTech company Johnson & Johnson.
Pre-market futures are gathering steam following this morning's slew of economic data, which was quite encouraging overall. Wholesale inflation and another round of Q2 earnings results, along with a New York manufacturing index, has seen the blue-chip Dow up from +99 points to +140 at this hour.
JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.